Title |
Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability
|
---|---|
Published in |
BMC Biotechnology, October 2012
|
DOI | 10.1186/1472-6750-12-77 |
Pubmed ID | |
Authors |
Elena Feshchenko, David G Rhodes, Rachael Felberbaum, Clifton McPherson, Joseph A Rininger, Penny Post, Manon MJ Cox |
Abstract |
The recent H1N1 influenza pandemic illustrated the shortcomings of the vaccine manufacturing process. The A/California/07/2009 H1N1 pandemic influenza vaccine or A(H1N1)pdm09 was available late and in short supply as a result of delays in production caused by low yields and poor antigen stability. Recombinant technology offers the opportunity to shorten manufacturing time. A trivalent recombinant hemagglutinin (rHA) vaccine candidate for seasonal influenza produced using the baculovirus expression vector system (BEVS) was shown to be as effective and safe as egg-derived trivalent inactivated vaccine (TIV) in human clinical studies. In this study, we describe the characterization of the A/California/07/2009 rHA protein and compare the H1N1 pandemic rHA to other seasonal rHA proteins. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Peru | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 56 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 11 | 20% |
Student > Ph. D. Student | 11 | 20% |
Researcher | 9 | 16% |
Other | 6 | 11% |
Student > Bachelor | 3 | 5% |
Other | 6 | 11% |
Unknown | 10 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 13 | 23% |
Biochemistry, Genetics and Molecular Biology | 8 | 14% |
Chemistry | 7 | 13% |
Immunology and Microbiology | 6 | 11% |
Medicine and Dentistry | 4 | 7% |
Other | 8 | 14% |
Unknown | 10 | 18% |